The agent delgocitinib is a broad-spectrum JAK inhibitor blocking signal pathways including JAK-1/2/3 and tyrosine kinase 2. In a previous study, delgocitinib was successful in patients with chronic hand eczema.
The study presented during the AAD VMX 2021 meeting was a randomised, vehicle-controlled, dose-ranging phase 2b trial involving adults with atopic dermatitis (AD) of at least 1-year duration (NCT03725722) [1]. Eligible patients had a mean body surface area (BSA) affected by AD of 10 and disease severity according to the investigators global assessment (IGA) ranging from mild to severe. Patients were treated with a vehicle cream or delgocitinib cream in 4 different doses (i.e. 1, 3, 8, and 20 mg/g), which was applied twice daily. The primary endpoint of the study was the change in EASI score from baseline to week 8.
Included in the analysis were 251 patients. In the highest dose group (20 mg), EASI score dropped by 7.6 from baseline to week 8 compared with 1.9 in the placebo group (P<0.05). With regard to change from baseline in EASI score, all delgocitinib doses separated distinctly from the vehicle arm by week 1, which continued up to week 8. “Clearly, the highest dose had the greatest efficacy,” Prof. Jonathan Silverberg (George Washington University, Washington DC, USA) emphasised during his presentation. The EASI 75 response rate at week 8 showed a similar pattern. In the highest dose group, this difference became significant as early as week 1 compared with the control group. Treatment with delgocitinib was accompanied by a significant improvement in the quality of life, assessed in the Dermatology Life Quality Index (DLQI).
“Itch is the most common and most burdensome symptom in AD,” Prof. Silverberg said. In this study, itch relief was assessed as secondary endpoint: patients had a baseline itch score of 6.1, which decreased by 4.6 points in the highest dose group by week 8 and by 2.8–3.0 point in the other delgocitinib arms, compared with 1.0 in the placebo group (P<0.05). Daily itch score declined significantly versus the control group by day 2 in all but the lowest dose of delgocitinib. The safety profile of the JAK inhibitor was comparable to that of the control group.
- Silverberg J, et al. The topical pan-JAK inhibitor delgocitinib in a cream formulation is efficacious with a favorable safety profile: results from an 8-week phase 2b dose-ranging trial in atopic dermatitis. AAD VMX 2021, 23-25 April.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Atopic dermatitis in children has a severe impact on their families Next Article
No increased risk of infection with long-term dupilumab for atopic dermatitis »
« Atopic dermatitis in children has a severe impact on their families Next Article
No increased risk of infection with long-term dupilumab for atopic dermatitis »
Table of Contents: AAD 2021
Featured articles
Letter from the Editor
Late-Breaking Abstracts
Small molecule effective in moderate-to-severe psoriasis
Bruton’s tyrosine kinase inhibition promising for pemphigus vulgaris
Bimekizumab superior to secukinumab in psoriasis
Etrasimod – a new mode of action for treatment of atopic dermatitis
Women at higher risk for dermatologic side effects during immunotherapy
Novel easy-to-use foam formulation clears scalp psoriasis in one-third of patients
Anti-cholinergic gel demonstrates superior long-term tolerability and efficacy in axillary hyperhidrosis
Psoriasis – The Beat Goes On
Psoriasis: The treatment armamentarium continues to grow
Psoriasis management in times of COVID-19: the knowledge is growing steadily
Lower burden of high-risk atherosclerotic plaques in psoriasis patients treated with biologics
COVID-19: What Dermatologists Need to Know
Psoriasis and hidradenitis suppurativa during COVID-19: keep calm and carry on
COVID-19 in children – cutaneous involvement is common
Cutaneous reactions after COVID-19 vaccination: an update
Novel Developments in Sun Protection
Sunless tanning and other developments in sun protection
What Is Hot in Atopic Dermatitis
Comorbidity is common in adult and paediatric atopic dermatitis patients
Significant improvements in the system armamentarium for AD treatment
Topical pan-JAK inhibitor cream safe and efficacious in atopic dermatitis
Hairy Matters – What Is New in Alopecia
Allergies: an underrated factor in alopecia pathogenesis
Botulinum toxin A: a contradictory role in hair loss
Platelet-rich plasma in androgenetic alopecia – hype or hope?
Acne – New Developments
New therapeutic options add value to current acne treatment
Nicotinamide and probiotics can support acne therapy
Pearls of the Posters
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com